Folfirinox is associated with a long-term survival benefit compared to gemcitabine-abraxane for neoadjuvant therapy before pancreatic cancer surgery

Background: FOLFIRINOX and Gemcitabine-Abraxane (G-A) are two of the most commonly utilized modern neoadjuvant regimens in treating pancreatic cancer, however, there are currently no large studies comparing survival by regimen in the neoadjuvant setting. Methods: Utilizing 100% fee-for-service Medicare claims from Jan, 2010 to Dec, 2017, we identified all Whipple procedures without vascular resection performed for pancreatic cancer. We evaluated...